HALO Stock Analysis: Halozyme Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 12.215m USD | 12M Return: 51.4% | US40637H1095 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 207M
EPS Trend: 84.2%
Qual. Beats: 0
Rev. Trend: 99.0%
Qual. Beats: 2
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Halozyme Therapeutics is a San Diego-based biopharmaceutical company founded in 1998 that develops and commercializes proprietary enzyme technology, primarily its patented recombinant human hyaluronidase enzyme (rHuPH20). This platform enables the subcutaneous (SC) delivery of biologics and other therapeutics that are typically administered intravenously. The company sells its own products such as Hylenex recombinant and XYOSTED (testosterone replacement therapy) while generating significant revenue through licensing its ENHANZE technology to major pharmaceutical partners including Roche, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol Myers Squibb, Takeda, and argenx. Through these collaborations, rHuPH20 is incorporated into approved partner products such as Herceptin Hylecta, Phesgo, Mabthera SC, Tecentriq SC, Ocrevus SC, HYQVIA, and DARZALEX, spanning indications in oncology, immunology, and neurology. The company operates in the United States, Switzerland, Belgium, Japan, and other international markets.
As a biotechnology company in the Health Care sector, Halozyme operates a hybrid business model combining proprietary product sales with a platform-licensing structure, earning upfront payments, milestone fees, and royalties tied to partner product sales. Its core value proposition is converting intravenous biologics into SC formulations, which can reduce administration time, ease healthcare provider burden, and improve patient convenience compared to traditional IV infusions.
- DARZALEX subcutaneous franchise drives double-digit royalty revenue growth
- New ENHANZE partnership deals with argenx and others expand royalty pipeline
- rHuPH20 patent litigation outcomes pose key long-term stock overhang
| Net Income: 413.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 4.96 > 1.0 |
| NWC/Revenue: 35.38% < 20% (prev 83.86%; Δ -48.48% < -1%) |
| CFO/TA 0.32 > 3% & CFO 818.6m > Net Income 413.6m |
| Net Debt (1.92b) to EBITDA (714.0m): 2.69 < 3 |
| Current Ratio: 2.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.2m) vs 12m ago -2.37% < -2% |
| Gross Margin: 78.18% > 18% (prev 81.19%; Δ -3.01% > 0.5%) |
| Asset Turnover: 71.85% > 50% (prev 57.39%; Δ 14.46% > 0%) |
| Interest Coverage Ratio: 29.73 > 6 (EBIT TTM 603.6m / Interest Expense TTM 20.3m) |
| A: 0.23 (Total Current Assets 933.0m - Total Current Liabilities 344.4m) / Total Assets 2.58b |
| B: 0.06 (Retained Earnings 151.3m / Total Assets 2.58b) |
| C: 0.26 (EBIT TTM 603.6m / Avg Total Assets 2.32b) |
| D: 0.06 (Book Value of Equity 143.5m / Total Liabilities 2.43b) |
| Altman-Z'' = 3.50 = A |
| DSRI: 1.02 (Receivables 455.8m/316.3m, Revenue 1.66b/1.18b) |
| GMI: 1.04 (GM 81.19% / 78.18%) |
| AQI: 1.45 (AQ_t 0.61 / AQ_t-1 0.42) |
| SGI: 1.41 (Revenue 1.66b / 1.18b) |
| TATA: -0.16 (NI 413.6m - CFO 818.6m) / TA 2.58b) |
| Beneish M = -2.43 (Cap -4..+1) = BBB |
As of August 26, 2026, the stock is trading at USD 109.32 with a total of 1,597,530 shares traded. Over the past week, the price has changed by +4.22%, over one month by +34.17%, over three months by +59.08% and over the past year by +51.39%.
Current recommended Stop Loss: 105.50 (which is 3.5% or 1.2 ATR below the current price).
Halozyme Therapeutics has received a consensus analysts rating of 3.63. Therefore, it is recommended to hold HALO.
- StrongBuy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 99.6 | -8.9% |
P/E Trailing = 30.7486
P/E Forward = 14.2248
P/S = 7.3417
P/B = 82.9117
P/EG = -2.5
Revenue TTM = 1.66b USD
EBIT TTM = 603.6m USD
EBITDA TTM = 714.0m USD
Long Term Debt = 1.94b USD (from longTermDebt, last quarter)
Short Term Debt = 209.0m USD (from shortTermDebt, last quarter)
Debt = 2.15b USD (from shortLongTermDebtTotal, last quarter) + Leases 2.55m
Net Debt = 1.92b USD (calculated: Debt 2.15b - CCE 231.0m)
Enterprise Value = 14.1b USD (12.2b + Debt 2.15b - CCE 231.0m)
Interest Coverage Ratio = 29.73 (Ebit TTM 603.6m / Interest Expense TTM 20.3m)
EV/FCF = 17.53x (Enterprise Value 14.1b / FCF TTM 806.2m)
FCF Yield = 5.70% (FCF TTM 806.2m / Enterprise Value 14.1b)
FCF Margin = 48.46% (FCF TTM 806.2m / Revenue TTM 1.66b)
Net Margin = 24.86% (Net Income TTM 413.6m / Revenue TTM 1.66b)
Gross Margin = 78.18% ((Revenue TTM 1.66b - Cost of Revenue TTM 363.1m) / Revenue TTM)
Gross Margin QoQ = 83.54% (prev 71.13%)
Tobins Q-Ratio = 5.48 (Enterprise Value 14.1b / Total Assets 2.58b)
Interest Expense / Debt = 0.94% (Interest Expense 20.3m / Debt 2.15b)
Taxrate = 29.10% (169.7m / 583.3m)
NOPAT = 428.0m (EBIT 603.6m * (1 - 29.10%))
Current Ratio = 2.71 (Total Current Assets 933.0m / Total Current Liabilities 344.4m)
Debt / Equity = 14.97 (Debt 2.15b / totalStockholderEquity, last quarter 143.5m)
Debt / EBITDA = 2.69 (Net Debt 1.92b / EBITDA 714.0m)
Debt / FCF = 2.38 (Net Debt 1.92b / FCF TTM 806.2m)
Total Stockholder Equity = 229.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 17.86% (Net Income 413.6m / Total Assets 2.58b)
RoE = 180.6% (Net Income TTM 413.6m / Total Stockholder Equity 229.0m)
RoCE = 27.86% (EBIT 603.6m / Capital Employed (Equity 229.0m + L.T.Debt 1.94b))
RoIC = 18.14% (NOPAT 428.0m / Invested Capital 2.36b)
WACC = 4.92% (E(12.2b)/V(14.4b) * Re(5.67%) + D(2.15b)/V(14.4b) * Rd(0.94%) * (1-Tc(0.29)))
Discount Rate = 5.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.50 | Cagr: -2.69%
[DCF] Terminal Value 77.97% ; FCFF base≈700.0m ; Y1≈802.4m ; Y5≈1.18b
[DCF] Fair Price = 139.7 (EV 17.8b - Net Debt 1.92b = Equity 15.9b / Shares 113.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.20 | EPS CAGR: 27.09% | SUE: 0.47 | # QB: 0
Revenue Correlation: 98.96 | Revenue CAGR: 31.47% | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-09-30): EPS=2.29 | Chg30d=+4.64% | Revisions=+17% | Analysts=6
EPS current Year (2026-12-31): EPS=8.58 | Chg30d=+5.09% | Revisions=+17% | GrowthEPS=+106.7% | GrowthRev=+32.7%
EPS next Year (2027-12-31): EPS=10.39 | Chg30d=+5.06% | Revisions=+29% | GrowthEPS=+21.2% | GrowthRev=+10.6%
[Analyst] Revisions Ratio: +31% (up=7, down=3)